Roche signs $100 million upfront deal with Alector to advance Parkinson's research

Roche announced a partnership with biotech Alector focused on neuroscience and Parkinson's disease, providing an upfront cash payment of $100 million.

The agreement aims to combine Roche's resources with Alector's pipeline, targeting development of novel therapies for Parkinson's. Details on milestones or downstream payments were not disclosed.

The deal follows a recent collapse of a separate partnership for Alector, highlighting Roche's interest in expanding its neurology portfolio.